Tullahoma (Tenn.) News (April 19) – “Our experience with cANK-101 in dogs with advanced melanoma strongly suggests that the drug is well tolerated. We are seeing few side effects in treated dogs,” said Dr. Fan, a professor of veterinary clinical medicine at the University of Illinois. “We are excited about observed cyto-reductive activities and will be following the dogs to determine the clinical impact and durability of response that cANK-101 may have on a difficult-to-treat cancer in dogs.”
Clinical Data Supports Therapeutic Potential of Anchored Immunotherapy
